BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36234743)

  • 1. Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure.
    Jia W; Luo S; Zhao W; Xu W; Zhong Y; Kong D
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
    Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
    Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors.
    Gong YP; Tang LQ; Liu TS; Liu ZP
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31775363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia.
    Xie C; He Y; Zhen M; Wang Y; Xu Y; Lou L
    Cancer Sci; 2017 Jul; 108(7):1476-1484. PubMed ID: 28418085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
    Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
    Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a natural PI3Kδ inhibitor through virtual screening and biological assay study.
    Guo JF; Ning ZQ; Wu X; Qiao YJ; Wang X
    Biochem Biophys Res Commun; 2019 Jan; 508(3):709-714. PubMed ID: 30528237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Novel PI3Kδ Selective Inhibitors by SVM-Based Multistage Virtual Screening and Molecular Dynamics Simulations.
    Liang JW; Wang S; Wang MY; Li SL; Li WQ; Meng FH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Wei M; Zhang X; Wang X; Song Z; Ding J; Meng LH; Zhang A
    Eur J Med Chem; 2017 Jan; 125():1156-1171. PubMed ID: 27846451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
    Ma CC; Zhang CM; Tang LQ; Liu ZP
    Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ.
    Somoza JR; Koditek D; Villaseñor AG; Novikov N; Wong MH; Liclican A; Xing W; Lagpacan L; Wang R; Schultz BE; Papalia GA; Samuel D; Lad L; McGrath ME
    J Biol Chem; 2015 Mar; 290(13):8439-46. PubMed ID: 25631052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structurally novel PI3Kδ/γ dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation.
    Tao Q; Chen Y; Liang X; Hu Y; Li J; Fang F; Wang H; Meng C; Liang J; Ma X; Gui S
    Eur J Med Chem; 2020 Apr; 191():112143. PubMed ID: 32078865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity.
    Teng Y; Li X; Ren S; Cheng Y; Xi K; Shen H; Ma W; Luo G; Xiang H
    Eur J Med Chem; 2020 Dec; 208():112865. PubMed ID: 32987316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
    Liu L; Shi B; Li X; Wang X; Lu X; Cai X; Huang A; Luo G; You Q; Xiang H
    Bioorg Med Chem; 2018 Aug; 26(15):4537-4543. PubMed ID: 30077608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
    Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies.
    Liu X; Wang A; Liang X; Liu J; Zou F; Chen C; Zhao Z; Deng Y; Wu H; Qi Z; Wang B; Wang L; Liu F; Xu Y; Wang W; Fernandes SM; Stone RM; Galinsky IA; Brown JR; Loh T; Griffin JD; Zhang S; Weisberg EL; Zhang X; Liu J; Liu Q
    Oncotarget; 2016 Aug; 7(33):53515-53525. PubMed ID: 27447747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies.
    Ma X; Wei J; Wang C; Gu D; Hu Y; Sheng R
    Eur J Med Chem; 2019 May; 170():112-125. PubMed ID: 30878826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia.
    Wang X; Zhang X; Li BS; Zhai X; Yang Z; Ding LX; Wang H; Liang C; Zhu W; Ding J; Meng LH
    Oncotarget; 2014 Nov; 5(21):10732-44. PubMed ID: 25313141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):651-656. PubMed ID: 29536777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
    Fan L; Wang C; Zhao L; Wang Z; Zhang X; Liu X; Cao L; Xu W; Li J
    Neoplasia; 2020 Dec; 22(12):714-724. PubMed ID: 33142237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of virtual screening against phosphoinositide 3-kinase delta: Integration of common feature pharmacophore and multicomplex-based molecular docking.
    Zhu J; Meng H; Li X; Jia L; Xu L; Cai Y; Chen Y; Jin J; Yu L
    Comput Biol Chem; 2024 Apr; 109():108011. PubMed ID: 38198965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.